Breaking News

Moderna, Samsung Biologics Ink COVID Vax Mfg. and Supply Pact

Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273 from its facilities in Incheon, South Korea.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna and Samsung Biologics entered a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.   Upon execution of the deal, technology transfer will begin immediately at Samsung’s facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters